| WB | 1/500 - 1/2000 | Human, Monkey |
| IF | 咨询技术 | Human, Monkey |
| IHC | 咨询技术 | Human, Monkey |
| ICC | 技术咨询 | Human, Monkey |
| FCM | 1/200 - 1/400 | Human, Monkey |
| Elisa | 1/10000 | Human, Monkey |
| Aliases | FGFR4; TKF; JTK2 |
| Entrez GeneID | 2264 |
| clone | 8A1G2 |
| WB Predicted band size | 88kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Monkey |
| Immunogen | Purified recombinant fragment of human CD334 (AA: extra 22-369) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于CD334(FGFR4)抗体的3篇参考文献概览，涵盖其在不同研究中的应用及机制：
1. **"Targeting FGFR4 with a therapeutic antibody inhibits tumor growth in triple-negative breast cancer models"**
*作者：Xie L, et al. (2018)*
**摘要**：研究开发了一种特异性抗FGFR4单克隆抗体，证实其通过阻断配体结合抑制下游MAPK信号通路，显著降低三阴性乳腺癌小鼠模型的肿瘤生长和转移。
2. **"FGFR4 promotes stroma-induced epithelial-to-mesenchymal transition in colorectal cancer"**
*作者：Matsumoto K, et al. (2020)*
**摘要**：利用CD334抗体揭示FGFR4在结直肠癌中通过介导肿瘤-间质交互作用驱动上皮间质转化(EMT)，靶向FGFR4可逆转化疗耐药性，为联合治疗提供依据。
3. **"A neutralizing anti-FGFR4 antibody inhibits hepatocellular carcinoma in vitro and in vivo"**
*作者：Zhao W, et al. (2016)*
**摘要**：报道一种中和性抗FGFR4抗体，可特异性阻断FGF19-FGFR4结合，抑制肝癌细胞增殖并诱导凋亡，动物实验显示其显著减少肿瘤体积且无显著毒性。
*注：以上文献信息基于领域内典型研究方向模拟，实际引用时建议通过PubMed或Web of Science核对原文详情。*
CD334. also known as fibroblast growth factor receptor 3 (FGFR3), is a transmembrane tyrosine kinase receptor involved in regulating cell proliferation, differentiation, and survival. It belongs to the FGFR family (FGFR1-4), which binds fibroblast growth factors (FGFs) to activate downstream signaling pathways, including MAPK/ERK, PI3K/AKT, and STAT. FGFR3 is critical in skeletal development, with gain-of-function mutations linked to genetic disorders like achondroplasia, while loss-of-function mutations are associated with conditions such as hypochondroplasia.
CD334 antibodies are essential tools for studying FGFR3 expression and function in both normal physiology and disease. They are widely used in techniques like immunohistochemistry (IHC), flow cytometry, and Western blotting to detect FGFR3 in tissues or cells. In cancer research, CD334 antibodies help identify FGFR3 overexpression or activation in malignancies like multiple myeloma, bladder cancer, and cervical cancer, where aberrant FGFR3 signaling drives tumor progression.
Therapeutic anti-FGFR3 antibodies and small-molecule inhibitors targeting FGFR3 have emerged as promising strategies in precision oncology. For example, drugs like erdafitinib (targeting FGFR alterations) highlight the clinical relevance of FGFR3 as a biomarker and therapeutic target. CD334 antibodies also aid in diagnosing FGFR3-related genetic disorders and monitoring treatment responses. Ongoing research continues to explore their potential in regenerative medicine and developmental biology, underscoring the multifaceted role of FGFR3 in health and disease.
×
